4.3 Review

Sphingolipids in Neurodegeneration

Journal

NEUROMOLECULAR MEDICINE
Volume 12, Issue 4, Pages 301-305

Publisher

HUMANA PRESS INC
DOI: 10.1007/s12017-010-8135-5

Keywords

Sphingolipid; Sphingomyelin; Ceramide; Neurodegeneration; Alzheimer's; HIV; Multiple sclerosis; Neurodegeneration; Synapse

Categories

Funding

  1. NIAAA NIH HHS [R01 AA017408] Funding Source: Medline
  2. NIA NIH HHS [R21 AG034849, R01 AG023471] Funding Source: Medline
  3. NIDA NIH HHS [R01 DA024593] Funding Source: Medline
  4. NIMH NIH HHS [P30 MH075673, R01 MH096636, R01 MH077542] Funding Source: Medline

Ask authors/readers for more resources

Although the brain contains a high content of sphingolipids, we know relatively little about the roles that sphingolipids play in regulating neural functions. Once regarded only for their structural roles in maintaining the integrity of cellular and sub-cellular compartments, it is now apparent that many sphingolipid species are biologically active and play important roles in regulating signaling events. Recent technological and scientific advances are rapidly increasing our knowledge of the roles that sphingolipids play in regulating normal neural activity. Likewise, we are beginning to understand how perturbations in sphingolipid metabolism contribute to the pathogenesis of a variety of neurodegenerative conditions. In this special issue of NeuroMolecular Medicine, we present a series of review articles that summarize new and emerging technologies for the analysis of sphingolipids, sphingolipid metabolic pathways, and how dysfunctions in sphingolipid metabolism contribute to neurodegeneration in lysosomal storage disorders, Alzheimer's disease and Multiple Sclerosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available